Frankfurt
18.08.25 | 08:06
1,590 Euro
-2,45 % -0,040
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,630 | 1,692 | 16:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.08. | CROSSJECT remains engaged during the summer break | 5 | GlobeNewswire (USA) | ||
| 24.06. | CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause | 6 | GlobeNewswire (USA) | ||
| 11.06. | CROSSJECT advances on the development of ZEPIZURE Junior, its solution for epilepsy crises in children | 115 | GlobeNewswire (Europe) | Press release CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children Announces the effective calibration of ZENEO® for the use of ZEPIZURE® in the... ► Artikel lesen | |
| 04.06. | CROSSJECT: Launch of a capital increase with preferential subscription rights for nearly 5 million euros | 1 | GlobeNewswire (USA) | ||
| 03.06. | Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00 | 77 | GlobeNewswire (Europe) | Press release Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00 Dijon, France 03 June 2025 (07.30 CET) -- CROSSJECT (ISIN: FR0011716265... ► Artikel lesen | |
| CROSSJECT Aktie jetzt für 0€ handeln | |||||
| 27.05. | CROSSJECT implements new manufacturing module to scale-up the ZENEO Factory 's versatility and capacity in anticipation of full product pipeline deployment | 3 | GlobeNewswire (USA) | ||
| 20.05. | CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval | 2 | GlobeNewswire (USA) | ||
| 15.05. | CROSSJECT's ZENEO needle-free autoinjector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors | 125 | GlobeNewswire (Europe) | Press Release CROSSJECT's ZENEO® needle-free auto-injector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors... ► Artikel lesen | |
| 07.05. | CROSSJECT provides updates on the EUA filing of ZEPIZURE | 2 | GlobeNewswire (USA) | ||
| 27.03. | CROSSJECT reports financial results for 2024 | 199 | GlobeNewswire (Europe) | Press Release CROSSJECT reports financial results for 2024 Continued satisfactory production of regulatory batches with a view to filing in Q2 2025.Recruitment of Tony Tipton as Chief Operating Officer... ► Artikel lesen | |
| 25.03. | CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO adrenal insufficiency program | 235 | GlobeNewswire (Europe) | Press Release CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhanced its collaboration with Eton Pharmaceuticals,... ► Artikel lesen | |
| 18.03. | CROSSJECT achieves key ZEPIZURE manufacturing batch stability milestones | 1 | GlobeNewswire (USA) | ||
| 12.02. | Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board | 204 | GlobeNewswire (Europe) | Dijon, FRANCE, February 12, 2025 - 0730 (CET) - Crossject (ISIN: FR0011716265; Euronext Growth: ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free... ► Artikel lesen | |
| 19.12.24 | Crossject confirms ZEPIZURE supply chain readiness with another successful ISO audit for Quality Management System | 168 | GlobeNewswire (Europe) | Crossject successfully passes another ISO 13485 audit for sites in Dijon and Gray (France)Company is ramping up supply chain to prepare for commercialization in U.S. Dijon, France, December 19, 2024... ► Artikel lesen | |
| 22.10.24 | Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE ahead of filing U.S. Emergency Use Authorization | 175 | GlobeNewswire (Europe) | Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file... ► Artikel lesen | |
| 23.09.24 | Crossject reports financial results and business highlights for the first six months of 2024 | 306 | GlobeNewswire (Europe) | Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in R&D and consolidation of operating income from BARDACompany on track to successfully file for the... ► Artikel lesen | |
| 19.08.24 | Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE Epilepsy Rescue Treatment | 327 | GlobeNewswire (Europe) | Press Release Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment Experienced executive to lead preparations... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 46,450 | +0,96 % | Fresenius-Aktie: Vor dem großen Befreiungsschlag | Mit etwas Verzögerung hat die Fresenius-Aktie dann doch noch deutlicher auf die guten Zahlen zum zweiten Quartal und der erhöhten Umsatzprognose reagiert (DER AKTIONÄR berichtete). Positive Analystenkommentare... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 47,040 | -0,06 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| INTUITIVE SURGICAL | 414,25 | +0,94 % | UNGLAUBLICHE Sondermeldung bei Intuitive Surgical Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
| SERNOVA BIOTHERAPEUTICS | 0,119 | -1,65 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes | LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics ("Sernova") (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals... ► Artikel lesen | |
| FAMICORD | 5,150 | +3,41 % | Original-Research: FamiCord AG (von Montega AG): Kaufen | Original-Research: FamiCord AG - von Montega AG 06.06.2025 / 17:08 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group. Für den Inhalt der Mitteilung... ► Artikel lesen | |
| GERATHERM MEDICAL | 3,100 | 0,00 % | Dividendenbekanntmachungen (28.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ASML HOLDING NV NL0010273215 - 1,6 EUR ATHOS IMMOBILIEN AG AT0000616701 - 0,8 EUR BRINKS COMPANY US1096961040 0,255 USD 0,2171 EUR DISO... ► Artikel lesen | |
| ALIGN TECHNOLOGY | 121,20 | -0,49 % | Pre-market Movers: VerifyMe, Psyence Biomedical, Pineapple Financial, Align Technology, Confluent | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green VerifyMe, Inc. (VRME) is up over 79% at $1.23.
Psyence... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,030 | -5,06 % | Beaking News: Vive la InsuJet - mit der Krankenkasse zum Erfolg? | ||
| PLUS THERAPEUTICS | 0,584 | -7,06 % | Plus Therapeutics Inc.: Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements | HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced... ► Artikel lesen | |
| CARDINAL HEALTH | 128,55 | +0,51 % | Prognose überzeugt nicht!: Cardinal Health übernimmt Solaris Health für 1,9 Milliarden Dollar - Aktie fällt | © Foto: SOPA Images - Sipa USADie Quartalszahlen des Gesundheitsdienstleister kommen an der Börse gar nicht gut an. Die Aktie fällt zum US-Handelsstart um 9 Prozent.Die US-amerikanische Pharma-Großhändler... ► Artikel lesen | |
| RESMED | 245,20 | +0,66 % | Dividendenbekanntmachungen (14.08.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABERDEEN GROUP PLC GB00BF8Q6K64 0,073 GBP 0,0846 EUR APERAM SA LU0569974404 - 0,5 EUR ASSURA PLC GB00BVGBWW93 0,0084 GBP 0,0097... ► Artikel lesen | |
| DAVITA | 115,25 | -0,43 % | DaVita, YMCA to host free health screenings for chronic conditions in 3 cities | ||
| ATOSSA THERAPEUTICS | 0,682 | +2,10 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update | FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required
Strong... ► Artikel lesen | |
| MEDICLIN | 3,080 | +3,36 % | EQS-News: MEDICLIN AG: MEDICLIN zieht positive Zwischenbilanz für das erste Halbjahr 2025 | EQS-News: MEDICLIN AG
/ Schlagwort(e): Halbjahresbericht/Halbjahresergebnis
MEDICLIN zieht positive Zwischenbilanz für das erste Halbjahr 2025
31.07.2025 / 13:13 CET/CEST
Für... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update | -- Increased Net Sales and Improved Loss from Operations in Q2 2025 vs. Prior Year Quarter --
-- Evofem Advances Plans for Special Meeting of Stockholders to Approve... ► Artikel lesen |
Das Unternehmen CROSSJECT SA kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,45 % bei einem Aktienkurs von 1,590 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CROSSJECT SA finden Sie auf Wallstreet Online.